Literature DB >> 9702438

Diabetic nephropathy in hypertransfused patients with beta-thalassemia. The role of oxidative stress.

R Loebstein1, D C Lehotay, X Luo, W Bartfay, B Tyler, G D Sher.   

Abstract

OBJECTIVE: Pathogenesis of diabetes-related microvascular complications involving oxidative damage by free radicals has been demonstrated. Free radical generation has been shown to derive largely from iron. Our objectives, therefore, were to determine if there is an increased incidence and/or an accelerated course of nephropathy in patients with diabetes, secondary to transfusional hemochromatosis, and to examine whether free radical activity contributes to the development of this complication. RESEARCH DESIGN AND METHODS: We evaluated nine patients with homozygous beta-thalassemia, complicated by clinically overt diabetes, for diabetic nephropathy over a 7-year period. Lipid peroxidation was quantified by measuring the presence of 20 saturated and unsaturated aldehydes, and results were compared with five normotensive type 1 diabetic patients without iron overload.
RESULTS: Nephropathy developed in five of nine patients (55%) after a mean duration of overt diabetes of 3.6 +/- 2.0 years. Three patients showed evidence of progressive microalbuminuria over a 7-year period (24.7-46.2, 52.2-430.1, and 17.7-54.3 micrograms/min, respectively). Two patients with borderline microalbuminuria (19.9 and 14.5 micrograms/min, respectively) demonstrated stable albumin excretion rates over the follow-up period. Total aldehyde concentration was significantly higher in beta-thalassemia diabetic patients, compared with nonthalassemic diabetic control subjects (8,106 +/- 1,280 vs. 4,594 +/- 247 nmol/l; P < 0.0001). The three patients with progressive microalbuminuria demonstrated significantly higher total aldehyde concentration, compared with the other beta-thalassemia diabetic patients with stable albumin excretion (9,428 +/- 337 vs. 7,445 +/- 1,003 nmol/l; P < 0.01). Serum vitamin E concentrations were significantly lower in beta-thalassemia patients with diabetes, compared with diabetic patients without iron overload (12.1 +/- 6.0 vs. 25.9 +/- 11.4 mumol/l; P = 0.02). Serum vitamin C concentrations did not differ between the two groups. Multiple regression analysis demonstrated total aldehyde concentration to be the most significant predictor for the development of microalbuminuria (P = 0.01), followed by the duration of diabetes (P = 0.02) and glycemic control (P = 0.02).
CONCLUSIONS: Early development and an accelerated course of diabetic nephropathy in iron-loaded patients with beta-thalassemia are observed. These findings may be attributed to high oxidative stress in these patients, which is secondary to iron-derived free radicals and to the patients' diminished antioxidant reserves.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9702438     DOI: 10.2337/diacare.21.8.1306

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

1.  Erythrocyte oxidant/antioxidant status of diabetic patients.

Authors:  S Büyükkoçak; H S Oztürk; M N Tamer; M Kaçmaz; M Y Cimen; I Durak
Journal:  J Endocrinol Invest       Date:  2000-04       Impact factor: 4.256

2.  Nutrition in Thalassemia: A Systematic Review of Deficiency, Relations to Morbidity, and Supplementation Recommendations.

Authors:  Elijah K Goldberg; Ashutosh Lal; Ellen B Fung
Journal:  J Pediatr Hematol Oncol       Date:  2022-01-01       Impact factor: 1.289

3.  Status of Catalase, Glutathione Peroxidase, Glutathione S-Transferase, and Myeloperoxidase Gene Polymorphisms in Beta-Thalassemia Major Patients to Assess Oxidative Injury and Its Association with Enzyme Activities.

Authors:  Poonam Tripathi; Sarita Agarwal; Satyendra Tewari; Kausik Mandal
Journal:  J Pediatr Genet       Date:  2021-04-12

4.  The ICET-A Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients.

Authors:  Vincenzo De Sanctis; Ashraf T Soliman; Heba Elsedfy; Saif Al Yaarubi; Nicos Skordis; Doaa Khater; Mohamed El Kholy; Iva Stoeva; Bernadette Fiscina; Michael Angastiniotis; Shahina Daar; Christos Kattamis
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-28       Impact factor: 2.576

5.  The clinical characteristics, biochemical parameters and insulin response to oral glucose tolerance test (OGTT) in 25 transfusion dependent β-thalassemia (TDT) patients recently diagnosed with diabetes mellitus (DM).

Authors:  Vincenzo De Sanctis; Ashraf Soliman; Ploutarchos Tzoulis; Shahina Daar; Mehran Karimi; Mohamed A Yassin; Gabriella Pozzobon; Christos Kattamis
Journal:  Acta Biomed       Date:  2022-01-19

6.  Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience.

Authors:  Vincenzo De Sanctis; Shahina Daar; Ashraf T Soliman; Ploutarchos Tzoulis; Mehran Karimi; Salvatore Di Maio; Christos Kattamis
Journal:  Acta Biomed       Date:  2022-03-14

Review 7.  Iron supplementation in the intensive care unit: when, how much, and by what route?

Authors:  Marc Lapointe
Journal:  Crit Care       Date:  2004-06-14       Impact factor: 9.097

8.  Prevalence, characteristics, and prognostic significance of HFE gene mutations in type 2 diabetes: the Fremantle Diabetes Study.

Authors:  Timothy M E Davis; John Beilby; Wendy A Davis; John K Olynyk; Gary P Jeffrey; Enrico Rossi; Conchita Boyder; David G Bruce
Journal:  Diabetes Care       Date:  2008-06-19       Impact factor: 19.112

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.